In addition, the KEYNOTE-091 trial (35) presented evidence that pembrolizumab significantly improved DFS in completely resected stage IB–IIIA NSCLC, irrespective of PD-L1 expression levels (HR, 0.76, P = 0.0014). This evidence concerns the gene CD274 and non-small cell lung carcinoma.